



Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	December 8, 2021 May 6, 2022

TRUDHESA™ (dihydroergotamine mesylate)

LENGTH OF AUTHORIZATION: Up to 6 months

INITIAL REVIEW CRITERIA:

- Patient must be ≥ 18 years of age.
- Patient must have a diagnosis of migraines.
- The drug must be prescribed for the acute treatment of migraine headaches.
- Patient must have a history of trial and failure within the last 6 months of the following:
 - One preferred triptan; **AND**
 - Concurrent use of **ONE** of the following prophylaxis products:
 - Amitriptyline
 - Beta Blocker
 - Topiramate
 - Divalproex Sodium
 - Valproic Acid

DOSING AND ADMINISTRATION:

- Refer to product labeling at <https://www.accessdata.fda.gov/scripts/cder/daf/>
- Available as 0.725 mg nasal spray.